ArticlePloS one2026

A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol.

Tomoya Kurokawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.